Document is current
Any future updates will be listed below
-
Authors
Gavriilidis, Prodromos
Mottaghy, Felix M.
Koole, Michel
van de Weijer, Tineke
Mitea, Cristina
van der Pol, Jochem A. J.
van Nijnatten, Thiemo J. A.
Jansen, Floris P.
Wierts, Roel https://orcid.org/0000-0002-9955-8754
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 27 December 2024
First Online: 29 January 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval for this study was granted by the medical ethics committee METC azM/UM, Maastricht, The Netherlands (Date: 09-July-2021, No: 2021–2795).
: Written informed consent was obtained from all individual participants included in the study.
: Informed consent was obtained from all participants to publish their anonymized data.
: Felix M. Mottaghy is medical advisor for NanoMab Technology Ltd. and Advanced Accelerator Applications (AAA) GmbH/Novartis and has recently received institutional grants from NanoMab Technology Ltd., Siemens, and GE Precision HealthCare LLC. He is also supported by the German Research Foundation (DFG) within the framework of the Research Training Group 2375 “Tumor-targeted Drug Delivery” (grant 331065168), the Clinical Research Unit CRU 5011 “Integrating emerging methods to advance translational kidney research (InteraKD)” (project 445703531). In addition, his research is funded by the German Federal Ministry of Research and Education (project 16GW0319K). Moreover, he is an editor in the European Journal of Nuclear Medicine and Molecular Imaging. Floris P. Jansen is employee of GE HealthCare. The other authors have no relevant financial or non-financial interests to disclose regarding this topic.
